Table 2.
Demographic features, clinical characters and therapeutic profiles of enrolled SLE patients.
| Patient Group | Nil | LN | DAH | p Values |
|---|---|---|---|---|
| Demographic f eature | ||||
| Patients number | 5 | 5 | 5 | |
| Age (year) | 35.4 ± 7.3 | 34.6 ± 9.3 | 36.0 ± 11.1 | NS |
| Female | 4 (80%) | 4 (80%) | 4 (80%) | NS |
| Clinical profile | ||||
| Disease period (years) | 5.4 ± 3.4 | 5.2 ± 4.3 | 4.6 ± 3.7 | NS |
| Activity score (SLEDAI-2K) | 2.2 ± 1.5 | 8.6 ± 2.4 | 19.2 ± 3.7 | * p < 0.01 |
| Involved organ number | 0.6 ± 0.5 | 2.8± 0.4 | 3.8 ± 0.4 | * p < 0.01 |
| Therapeutic modality | ||||
| Corticosteroid | 5 (100%) | 5 (100%) | 5 (100%) | NS |
| Cyclophosphamide | 0 (0%) | 4 (80%) | 4 (80%) | * p < 0.05 |
| Mycophenolate mofetil | 0 (0%) | 3 (60%) | 2 (40%) | NS |
| Azathioprine | 2 (40%) | 2 (40%) | 3 (60%) | NS |
| Rituximab | 0 (0%) | 1 (20%) | 2 (40%) | NS |
| Plasmapheresis | 0 (0%) | 0 (0%) | 1 (20%) | NS |
| Mechanic ventilator | 0 (0%) | 0 (0%) | 5 (100%) | #p < 0.01 |
| ECMO | 0 (0%) | 0 (0%) | 1 (20%) | NS |
DAH: diffuse alveolar hemorrhage, ECMO: extracorporeal membrane oxygenation, LN: lupus nephritis, NS: not significant, SLE: systemic lupus erythematosus. * DAH or LN versus Nil, # DAH versus LN or Nil.